Evogene (EVGN) Stock
Israeli computational biology firm licensing crop improvement technology. Here's the price, business snapshot, and what's worth knowing about Evogene in October 2026.
Evogene Ltd (EVGN) is an Israel-based computational biology company developing crop traits, biologicals and precision ag solutions using proprietary algorithms and genomics platforms. It licences technology to partners and advances a pipeline of trait candidates and biological products aimed at improving yield, stress tolerance and pest resistance. For investors, key points are Evogene’s technology-driven model, reliance on partnerships and R&D milestones, and the typical long timelines of agricultural biotech development. The company’s small market capitalisation suggests higher volatility and potential liquidity constraints; results from trials, partner deals or regulatory steps can markedly move the share price. Financial strength, cash burn and the success of collaborations are material considerations. This summary provides general, educational information — not personalised investment advice — and investors should be aware that returns are not guaranteed and company prospects can decline as well as improve.
Evogene (EVGN) Stock Forecast
Analyst price target, next 12 months
$7.82
+1739.7% vs today's $0.43
Price range over the last 12 months
Close to its 12-month low
Analysts covering Evogene have a consensus 12-month target of $7.82, above the current price of $0.43.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Evogene's stock with a target price of $7.82, indicating strong upside potential.
Financial Health
Evogene is generating moderate revenue and cash flow, with decent profit margins for its operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Computational Biology Edge
Evogene’s algorithms aim to speed discovery of crop traits and biologicals, which may reduce time to candidate identification — though laboratory and field validation remain uncertain.
Partnerships Drive Commercialisation
The company often licences technology to larger agricultural firms to scale products, so partnership deals and collaborations materially affect future revenue prospects.
Micro‑cap Risk Profile
With a market cap near $11m, shares can be volatile and liquidity limited; financial runway and funding needs are important considerations for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
